CA2548347A1 - Procedes pour generer une immunite a un antigene - Google Patents

Procedes pour generer une immunite a un antigene Download PDF

Info

Publication number: CA2548347A1
Authority: CA; Canada
Prior art keywords: antigen; vector; ligand; protein; fusion protein
Prior art date: 2003-12-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002548347A

Other languages

English (en)

Inventor

Albert Deisseroth

Yucheng Tang

Xiang-Ming Fang

Wei-Wei Zhang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sidney Kimmel Cancer Center

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-11

Filing date

2004-12-10

Publication date

2005-06-30

2004-12-10 Application filed by Individual filed Critical Individual

2005-06-30 Publication of CA2548347A1 publication Critical patent/CA2548347A1/fr

Status Abandoned legal-status Critical Current

Links

108091007433 antigens Proteins 0.000 title claims abstract description 213
102000036639 antigens Human genes 0.000 title claims abstract description 213
239000000427 antigen Substances 0.000 title claims abstract description 211
238000000034 method Methods 0.000 title claims abstract description 123
230000036039 immunity Effects 0.000 title claims description 22
239000013598 vector Substances 0.000 claims abstract description 227
102100032937 CD40 ligand Human genes 0.000 claims abstract description 140
108010029697 CD40 Ligand Proteins 0.000 claims abstract description 139
206010028980 Neoplasm Diseases 0.000 claims abstract description 114
108020001507 fusion proteins Proteins 0.000 claims abstract description 105
102000037865 fusion proteins Human genes 0.000 claims abstract description 105
239000013604 expression vector Substances 0.000 claims abstract description 56
238000013518 transcription Methods 0.000 claims abstract description 47
230000035897 transcription Effects 0.000 claims abstract description 47
230000028993 immune response Effects 0.000 claims abstract description 41
201000011510 cancer Diseases 0.000 claims abstract description 34
239000012678 infectious agent Substances 0.000 claims abstract description 18
108090000623 proteins and genes Proteins 0.000 claims description 123
102000004169 proteins and genes Human genes 0.000 claims description 110
210000004027 cell Anatomy 0.000 claims description 92
102000015728 Mucins Human genes 0.000 claims description 87
108010063954 Mucins Proteins 0.000 claims description 87
102100034256 Mucin-1 Human genes 0.000 claims description 72
101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 68
108010076504 Protein Sorting Signals Proteins 0.000 claims description 40
108090000765 processed proteins & peptides Proteins 0.000 claims description 23
230000003612 virological effect Effects 0.000 claims description 22
230000001086 cytosolic effect Effects 0.000 claims description 21
239000013603 viral vector Substances 0.000 claims description 18
230000003248 secreting effect Effects 0.000 claims description 17
101001133081 Homo sapiens Mucin-2 Proteins 0.000 claims description 15
102100034263 Mucin-2 Human genes 0.000 claims description 15
239000002671 adjuvant Substances 0.000 claims description 13
238000004519 manufacturing process Methods 0.000 claims description 13
101000868215 Homo sapiens CD40 ligand Proteins 0.000 claims description 12
101000972284 Homo sapiens Mucin-3A Proteins 0.000 claims description 10
101000972286 Homo sapiens Mucin-4 Proteins 0.000 claims description 10
102100022693 Mucin-4 Human genes 0.000 claims description 10
101000972278 Homo sapiens Mucin-6 Proteins 0.000 claims description 9
-1 MUC8 Proteins 0.000 claims description 9
102100022497 Mucin-3A Human genes 0.000 claims description 9
102100022493 Mucin-6 Human genes 0.000 claims description 9
230000001580 bacterial effect Effects 0.000 claims description 9
101000972273 Homo sapiens Mucin-7 Proteins 0.000 claims description 8
102100022492 Mucin-7 Human genes 0.000 claims description 8
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 7
101000623897 Homo sapiens Mucin-12 Proteins 0.000 claims description 7
241000701806 Human papillomavirus Species 0.000 claims description 7
102100023143 Mucin-12 Human genes 0.000 claims description 7
102000004196 processed proteins & peptides Human genes 0.000 claims description 7
201000009030 Carcinoma Diseases 0.000 claims description 6
101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 6
101000972285 Homo sapiens Mucin-3B Proteins 0.000 claims description 6
101001121378 Homo sapiens Oviduct-specific glycoprotein Proteins 0.000 claims description 6
102100023123 Mucin-16 Human genes 0.000 claims description 6
102100022702 Mucin-3B Human genes 0.000 claims description 6
102100026327 Oviduct-specific glycoprotein Human genes 0.000 claims description 6
230000001472 cytotoxic effect Effects 0.000 claims description 6
239000003623 enhancer Substances 0.000 claims description 6
239000001963 growth medium Substances 0.000 claims description 6
229920001184 polypeptide Polymers 0.000 claims description 6
101000623900 Homo sapiens Mucin-13 Proteins 0.000 claims description 5
101000623905 Homo sapiens Mucin-15 Proteins 0.000 claims description 5
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 5
102100023124 Mucin-13 Human genes 0.000 claims description 5
102100023128 Mucin-15 Human genes 0.000 claims description 5
208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
231100000433 cytotoxic Toxicity 0.000 claims description 5
206010008342 Cervix carcinoma Diseases 0.000 claims description 4
241000701024 Human betaherpesvirus 5 Species 0.000 claims description 4
201000010881 cervical cancer Diseases 0.000 claims description 4
230000003362 replicative effect Effects 0.000 claims description 4
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 3
230000002538 fungal effect Effects 0.000 claims description 2
208000015181 infectious disease Diseases 0.000 claims description 2
101000972276 Homo sapiens Mucin-5B Proteins 0.000 claims 4
101000972282 Homo sapiens Mucin-5AC Proteins 0.000 claims 3
102100022496 Mucin-5AC Human genes 0.000 claims 3
102100022494 Mucin-5B Human genes 0.000 claims 3
210000005260 human cell Anatomy 0.000 claims 3
208000035473 Communicable disease Diseases 0.000 claims 1
244000005700 microbiome Species 0.000 claims 1
230000001902 propagating effect Effects 0.000 claims 1
230000037452 priming Effects 0.000 abstract description 3
230000002023 papillomaviral effect Effects 0.000 abstract 1
238000002347 injection Methods 0.000 description 41
239000007924 injection Substances 0.000 description 41
241000699670 Mus sp. Species 0.000 description 33
210000001744 T-lymphocyte Anatomy 0.000 description 32
238000010254 subcutaneous injection Methods 0.000 description 31
239000007929 subcutaneous injection Substances 0.000 description 31
108020004414 DNA Proteins 0.000 description 30
150000001413 amino acids Chemical class 0.000 description 29
241001465754 Metazoa Species 0.000 description 24
241000699666 Mus <mouse, genus> Species 0.000 description 20
108010008707 Mucin-1 Proteins 0.000 description 19
210000004443 dendritic cell Anatomy 0.000 description 19
238000011282 treatment Methods 0.000 description 19
239000013612 plasmid Substances 0.000 description 18
238000007920 subcutaneous administration Methods 0.000 description 17
230000014509 gene expression Effects 0.000 description 16
229960005486 vaccine Drugs 0.000 description 15
230000012010 growth Effects 0.000 description 14
210000002966 serum Anatomy 0.000 description 14
238000011144 upstream manufacturing Methods 0.000 description 14
229940051875 mucins Drugs 0.000 description 13
210000004881 tumor cell Anatomy 0.000 description 13
241000699660 Mus musculus Species 0.000 description 12
108020004999 messenger RNA Proteins 0.000 description 12
238000011830 transgenic mouse model Methods 0.000 description 12
102000007298 Mucin-1 Human genes 0.000 description 11
208000026310 Breast neoplasm Diseases 0.000 description 10
239000012634 fragment Substances 0.000 description 10
101100504181 Arabidopsis thaliana GCS1 gene Proteins 0.000 description 9
206010006187 Breast cancer Diseases 0.000 description 9
101100346932 Mus musculus Muc1 gene Proteins 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
230000009261 transgenic effect Effects 0.000 description 9
108010029485 Protein Isoforms Proteins 0.000 description 8
102000001708 Protein Isoforms Human genes 0.000 description 8
238000013459 approach Methods 0.000 description 8
230000000694 effects Effects 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
230000002441 reversible effect Effects 0.000 description 8
125000006850 spacer group Chemical group 0.000 description 8
238000002255 vaccination Methods 0.000 description 8
101100346929 Homo sapiens MUC1 gene Proteins 0.000 description 7
108010074328 Interferon-gamma Proteins 0.000 description 7
238000012408 PCR amplification Methods 0.000 description 7
210000000612 antigen-presenting cell Anatomy 0.000 description 7
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 7
238000011161 development Methods 0.000 description 7
230000018109 developmental process Effects 0.000 description 7
239000003814 drug Substances 0.000 description 7
102000057860 human MUC1 Human genes 0.000 description 7
239000000203 mixture Substances 0.000 description 7
239000002773 nucleotide Substances 0.000 description 7
125000003729 nucleotide group Chemical group 0.000 description 7
239000002245 particle Substances 0.000 description 7
206010011968 Decreased immune responsiveness Diseases 0.000 description 6
101100059511 Homo sapiens CD40LG gene Proteins 0.000 description 6
210000004072 lung Anatomy 0.000 description 6
108091008146 restriction endonucleases Proteins 0.000 description 6
238000012360 testing method Methods 0.000 description 6
239000013638 trimer Substances 0.000 description 6
241000701022 Cytomegalovirus Species 0.000 description 5
102000008070 Interferon-gamma Human genes 0.000 description 5
108091008874 T cell receptors Proteins 0.000 description 5
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 5
125000003275 alpha amino acid group Chemical group 0.000 description 5
230000000890 antigenic effect Effects 0.000 description 5
238000010276 construction Methods 0.000 description 5
229940079593 drug Drugs 0.000 description 5
229960003130 interferon gamma Drugs 0.000 description 5
230000005923 long-lasting effect Effects 0.000 description 5
210000001165 lymph node Anatomy 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
239000000047 product Substances 0.000 description 5
108010001336 Horseradish Peroxidase Proteins 0.000 description 4
206010058467 Lung neoplasm malignant Diseases 0.000 description 4
206010056342 Pulmonary mass Diseases 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
238000001574 biopsy Methods 0.000 description 4
210000000481 breast Anatomy 0.000 description 4
210000000170 cell membrane Anatomy 0.000 description 4
230000007969 cellular immunity Effects 0.000 description 4
230000021615 conjugation Effects 0.000 description 4
230000002950 deficient Effects 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
210000002919 epithelial cell Anatomy 0.000 description 4
150000002632 lipids Chemical class 0.000 description 4
201000005202 lung cancer Diseases 0.000 description 4
208000020816 lung neoplasm Diseases 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000010076 replication Effects 0.000 description 4
239000007787 solid Substances 0.000 description 4
210000000952 spleen Anatomy 0.000 description 4
230000003393 splenic effect Effects 0.000 description 4
241000701161 unidentified adenovirus Species 0.000 description 4
101710164309 56 kDa type-specific antigen Proteins 0.000 description 3
101150013553 CD40 gene Proteins 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
238000011510 Elispot assay Methods 0.000 description 3
102000018997 Growth Hormone Human genes 0.000 description 3
108010051696 Growth Hormone Proteins 0.000 description 3
101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 3
102000013462 Interleukin-12 Human genes 0.000 description 3
108010065805 Interleukin-12 Proteins 0.000 description 3
101000868216 Mus musculus CD40 ligand Proteins 0.000 description 3
101000972289 Mus musculus Mucin-2 Proteins 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
206010061902 Pancreatic neoplasm Diseases 0.000 description 3
241000237988 Patellidae Species 0.000 description 3
102100034763 Peroxiredoxin-2 Human genes 0.000 description 3
241000700605 Viruses Species 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000003321 amplification Effects 0.000 description 3
238000000137 annealing Methods 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000010367 cloning Methods 0.000 description 3
208000029742 colonic neoplasm Diseases 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
230000029087 digestion Effects 0.000 description 3
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
210000002472 endoplasmic reticulum Anatomy 0.000 description 3
230000006870 function Effects 0.000 description 3
238000001476 gene delivery Methods 0.000 description 3
239000000122 growth hormone Substances 0.000 description 3
238000002649 immunization Methods 0.000 description 3
230000003053 immunization Effects 0.000 description 3
201000010985 invasive ductal carcinoma Diseases 0.000 description 3
239000003446 ligand Substances 0.000 description 3
239000002502 liposome Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000002493 microarray Methods 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
208000008443 pancreatic carcinoma Diseases 0.000 description 3
230000008569 process Effects 0.000 description 3
210000002307 prostate Anatomy 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
238000009877 rendering Methods 0.000 description 3
230000004044 response Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
210000004989 spleen cell Anatomy 0.000 description 3
238000001709 templated self-assembly Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
206010052747 Adenocarcinoma pancreas Diseases 0.000 description 2
108700028369 Alleles Proteins 0.000 description 2
108091093088 Amplicon Proteins 0.000 description 2
208000003950 B-cell lymphoma Diseases 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
108010078791 Carrier Proteins Proteins 0.000 description 2
208000000668 Chronic Pancreatitis Diseases 0.000 description 2
239000004971 Cross linker Substances 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
206010053759 Growth retardation Diseases 0.000 description 2
102000025850 HLA-A2 Antigen Human genes 0.000 description 2
108010074032 HLA-A2 Antigen Proteins 0.000 description 2
102100032606 Heat shock factor protein 1 Human genes 0.000 description 2
108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
101000867525 Homo sapiens Heat shock factor protein 1 Proteins 0.000 description 2
102000002265 Human Growth Hormone Human genes 0.000 description 2
108010000521 Human Growth Hormone Proteins 0.000 description 2
239000000854 Human Growth Hormone Substances 0.000 description 2
241000341655 Human papillomavirus type 16 Species 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
102100037850 Interferon gamma Human genes 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
101150114927 MUC1 gene Proteins 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
241000713333 Mouse mammary tumor virus Species 0.000 description 2
241000711408 Murine respirovirus Species 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
206010033649 Pancreatitis chronic Diseases 0.000 description 2
108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
108010071390 Serum Albumin Proteins 0.000 description 2
102000007562 Serum Albumin Human genes 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
230000024932 T cell mediated immunity Effects 0.000 description 2
206010042971 T-cell lymphoma Diseases 0.000 description 2
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
108020005202 Viral DNA Proteins 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
230000004075 alteration Effects 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
239000003124 biologic agent Substances 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000000120 cytopathologic effect Effects 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
239000003596 drug target Substances 0.000 description 2
238000009585 enzyme analysis Methods 0.000 description 2
238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
230000004927 fusion Effects 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
102000051957 human ERBB2 Human genes 0.000 description 2
229940116978 human epidermal growth factor Drugs 0.000 description 2
230000004727 humoral immunity Effects 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
230000006698 induction Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
206010061289 metastatic neoplasm Diseases 0.000 description 2
239000004005 microsphere Substances 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
210000004877 mucosa Anatomy 0.000 description 2
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
230000001613 neoplastic effect Effects 0.000 description 2
238000011275 oncology therapy Methods 0.000 description 2
108091008819 oncoproteins Proteins 0.000 description 2
102000027450 oncoproteins Human genes 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
210000000496 pancreas Anatomy 0.000 description 2
201000002094 pancreatic adenocarcinoma Diseases 0.000 description 2
201000002528 pancreatic cancer Diseases 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
210000005000 reproductive tract Anatomy 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
235000002639 sodium chloride Nutrition 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
FPKVOQKZMBDBKP-UHFFFAOYSA-N 1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 FPKVOQKZMBDBKP-UHFFFAOYSA-N 0.000 description 1
WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 1
KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
241001136782 Alca Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
206010059313 Anogenital warts Diseases 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
241000702673 Bovine rotavirus Species 0.000 description 1
206010055113 Breast cancer metastatic Diseases 0.000 description 1
102000000905 Cadherin Human genes 0.000 description 1
108050007957 Cadherin Proteins 0.000 description 1
101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
108090000565 Capsid Proteins Proteins 0.000 description 1
102100023321 Ceruloplasmin Human genes 0.000 description 1
206010008263 Cervical dysplasia Diseases 0.000 description 1
102000009410 Chemokine receptor Human genes 0.000 description 1
108050000299 Chemokine receptor Proteins 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
208000000907 Condylomata Acuminata Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
206010058314 Dysplasia Diseases 0.000 description 1
101150029662 E1 gene Proteins 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102100031982 Ephrin type-B receptor 3 Human genes 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108700039887 Essential Genes Proteins 0.000 description 1
108091029865 Exogenous DNA Proteins 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
206010071602 Genetic polymorphism Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
102000009465 Growth Factor Receptors Human genes 0.000 description 1
108010009202 Growth Factor Receptors Proteins 0.000 description 1
102100033067 Growth factor receptor-bound protein 2 Human genes 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
101000871017 Homo sapiens Growth factor receptor-bound protein 2 Proteins 0.000 description 1
101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
101000623904 Homo sapiens Mucin-17 Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010043496 Immunoglobulin Idiotypes Proteins 0.000 description 1
108010090227 Immunoglobulin kappa-Chains Proteins 0.000 description 1
102000012960 Immunoglobulin kappa-Chains Human genes 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010023825 Laryngeal cancer Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
206010054949 Metaplasia Diseases 0.000 description 1
206010027458 Metastases to lung Diseases 0.000 description 1
108091092878 Microsatellite Proteins 0.000 description 1
208000032818 Microsatellite Instability Diseases 0.000 description 1
102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
102100023125 Mucin-17 Human genes 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101001016849 Mus musculus Heat shock protein HSP 90-alpha Proteins 0.000 description 1
101000985444 Mus musculus Heat shock protein HSP 90-beta Proteins 0.000 description 1
101100124877 Mus musculus Hsf1 gene Proteins 0.000 description 1
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
238000009004 PCR Kit Methods 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
108010067787 Proteoglycans Proteins 0.000 description 1
102000016611 Proteoglycans Human genes 0.000 description 1
101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
206010067868 Skin mass Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
101150033527 TNF gene Proteins 0.000 description 1
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
108010034949 Thyroglobulin Proteins 0.000 description 1
102000009843 Thyroglobulin Human genes 0.000 description 1
108091005906 Type I transmembrane proteins Proteins 0.000 description 1
108010059722 Viral Fusion Proteins Proteins 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
229940027570 adenoviral vector vaccine Drugs 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
201000004201 anogenital venereal wart Diseases 0.000 description 1
230000006023 anti-tumor response Effects 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
230000005975 antitumor immune response Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
238000003491 array Methods 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
210000000069 breast epithelial cell Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
238000010805 cDNA synthesis kit Methods 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
238000009566 cancer vaccine Methods 0.000 description 1
229940022399 cancer vaccine Drugs 0.000 description 1
210000000234 capsid Anatomy 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000011712 cell development Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
230000007248 cellular mechanism Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
201000002758 colorectal adenoma Diseases 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000002153 concerted effect Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000000139 costimulatory effect Effects 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
210000005220 cytoplasmic tail Anatomy 0.000 description 1
238000002784 cytotoxicity assay Methods 0.000 description 1
231100000263 cytotoxicity test Toxicity 0.000 description 1
230000034994 death Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000000779 depleting effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
210000003162 effector t lymphocyte Anatomy 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
230000009841 epithelial lesion Effects 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
125000004185 ester group Chemical class 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
210000001156 gastric mucosa Anatomy 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000003208 gene overexpression Methods 0.000 description 1
230000008303 genetic mechanism Effects 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
235000020256 human milk Nutrition 0.000 description 1
210000004251 human milk Anatomy 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
239000008101 lactose Substances 0.000 description 1
206010023841 laryngeal neoplasm Diseases 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
238000011068 loading method Methods 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
229940071648 metered dose inhaler Drugs 0.000 description 1
108010041420 microbial alkaline proteinase inhibitor Proteins 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
108010071421 milk fat globule Proteins 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
229940035032 monophosphoryl lipid a Drugs 0.000 description 1
JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
239000013642 negative control Substances 0.000 description 1
GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
230000001254 nonsecretory effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
210000004923 pancreatic tissue Anatomy 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229940023041 peptide vaccine Drugs 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
230000001855 preneoplastic effect Effects 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
235000017709 saponins Nutrition 0.000 description 1
210000005212 secondary lymphoid organ Anatomy 0.000 description 1
125000004085 sialosyl group Chemical group 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
238000010572 single replacement reaction Methods 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229940032094 squalane Drugs 0.000 description 1
229940031439 squalene Drugs 0.000 description 1
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
210000002536 stromal cell Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
229960002175 thyroglobulin Drugs 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000005945 translocation Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
238000005829 trimerization reaction Methods 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
229940126580 vector vaccine Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000017613 viral reproduction Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Toxicology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CA002548347A 2003-12-11 2004-12-10 Procedes pour generer une immunite a un antigene Abandoned CA2548347A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US59201603P	2003-12-11	2003-12-11
US60/529,016		2003-12-11
PCT/US2004/041690 WO2005058950A2 (fr)	2003-12-11	2004-12-10	Procedes pour generer une immunite a un antigene

Publications (1)

Publication Number	Publication Date
CA2548347A1 true CA2548347A1 (fr)	2005-06-30

Family

ID=34700248

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002548347A Abandoned CA2548347A1 (fr)	2003-12-11	2004-12-10	Procedes pour generer une immunite a un antigene

Country Status (3)

Country	Link
EP (1)	EP1720905A2 (fr)
CA (1)	CA2548347A1 (fr)
WO (1)	WO2005058950A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006061414A1 (fr) *	2004-12-09	2006-06-15	Ingenium Pharmaceuticals Ag	Procedes et agents utilises dans le traitement d'etats caracterises par l'hyperproduction/ hypersecretion de mucus
EP1951862B1 (fr)	2005-11-07	2013-07-24	MicroVAX, LLC	Vaccin à base de protéine de fusion portant un ligand cd40
PL2066339T3 (pl)	2006-09-18	2015-02-27	Univ Arkansas	Kompozycje i sposoby zwiększania odpowiedzi immunologicznych
US10174100B1 (en) *	2006-11-06	2019-01-08	Microvax, Llc	Multivalent DNA composition for Yersinia pestis
EP3061462B1 (fr)	2007-07-02	2019-02-27	Etubics Corporation	Procédés et compositions permettant de produire un vecteur d'adénovirus destiné à être utilisé avec des vaccinations multiples
JP2011502165A (ja)	2007-10-30	2011-01-20	ザボードオブトラスティーズオブザユニバーシティオブアーカンソー	鞭毛細菌に対する免疫応答を強化する組成物および方法
AU2008318357B2 (en)	2007-11-01	2015-01-22	The Board Of Trustees Of The University Of Arkansas	Compositions and methods of enhancing immune responses to eimeria
WO2011091255A1 (fr)	2010-01-21	2011-07-28	The Board Of Trustees Of The University Of Arkansas	Vecteurs de vaccin et procédés d'amplification de réponses immunitaires
MX377650B (es)	2010-06-09	2025-03-11	Univ Arkansas	Vacuna y métodos para reducir una infección por campylobacter.
WO2014031178A1 (fr)	2012-08-24	2014-02-27	Etubics Corporation	Vecteur adénoviral à réplication déficiente, utile en vaccination
AR094791A1 (es)	2013-02-14	2015-08-26	Univ Arkansas	Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o para limitar una infección por eimeria
MX376350B (es)	2013-03-15	2025-03-07	Univ Arkansas	Vectores para vacuna y uso de los mismos para aumentar la respuesta inmune contra patógenos entericos.
CN104345152B (zh) *	2013-08-08	2016-09-21	中国人民解放军第二军医大学东方肝胆外科医院	MUC15与p-AKT在制备肝癌预后评估试剂盒中的应用
EP3256140B1 (fr)	2015-01-09	2020-04-01	Etubics Corporation	Compositions pour la vaccination contre le virus ebola
JP6647315B2 (ja) *	2015-01-09	2020-02-14	イーチュービクスコーポレイション	組み合わせ免疫療法のための方法および組成物
JP6744318B2 (ja) *	2015-02-06	2020-08-26	ヒートバイオロジクス，インコーポレイテッド	ワクチンおよび共刺激分子を共発現するベクター
EP3286213B1 (fr)	2015-04-20	2021-08-04	Etubics Corporation	Méthodes et compositions d'immunothérapie combinée
EP3452069A4 (fr)	2016-05-03	2020-02-12	The Board of Trustees of the University of Arkansas	Vecteur vaccinal de levure comprenant des polypeptides immunostimulants et antigéniques et ses procédés d'utilisation
CA3040123A1 (fr)	2016-10-11	2018-04-19	University Of Miami	Vecteurs et cellules de vaccin pour immunite contre le virus zika
WO2018187260A1 (fr)	2017-04-04	2018-10-11	Heat Biologics, Inc.	Vaccination intratumorale

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60136334D1 (en) *	2000-02-02	2008-12-11	Us Health	Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff

2004
- 2004-12-10 WO PCT/US2004/041690 patent/WO2005058950A2/fr not_active Ceased
- 2004-12-10 EP EP04813939A patent/EP1720905A2/fr not_active Withdrawn
- 2004-12-10 CA CA002548347A patent/CA2548347A1/fr not_active Abandoned

Also Published As

Publication number	Publication date
WO2005058950A3 (fr)	2006-03-02
WO2005058950A2 (fr)	2005-06-30
EP1720905A2 (fr)	2006-11-15

Publication	Publication Date	Title
US9353167B2 (en)	2016-05-31	Methods for generating immunity to antigen
US9757438B2 (en)	2017-09-12	Mucin antigen vaccine
CA2548347A1 (fr)	2005-06-30	Procedes pour generer une immunite a un antigene
US20060286074A1 (en)	2006-12-21	Methods for immunotherapy of cancer
JP4662708B2 (ja)	2011-03-30	エクソゾームにタンパク質を標的化する方法および組成物
US7662586B2 (en)	2010-02-16	Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof
CA2509980C (fr)	2012-12-18	Vaccin a vecteur adenoviral
WO2019101062A1 (fr)	2019-05-31	Vaccin recombiné et son application
WO2008012237A1 (fr)	2008-01-31	Construction de multiples antigènes et leur utilisation
JP2008504219A (ja)	2008-02-14	抗原に対する免疫を生じさせる方法
US20060286114A1 (en)	2006-12-21	Synthetic gene encoding rhesus monkey carcinoembryonic antigen and uses thereof
JP2005526511A (ja)	2005-09-08	ワクチン

Legal Events

Date	Code	Title	Description
2009-12-08	EEER	Examination request
2010-12-10	FZDE	Discontinued